Pulmatrix (NASDAQ:PULM) Stock Passes Above 50-Day Moving Average – Should You Sell?

Shares of Pulmatrix, Inc. (NASDAQ:PULM) crossed above its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $1.36 and traded as high as $1.7250. Pulmatrix shares last traded at $1.64, with a volume of 27,450 shares changing hands.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Pulmatrix in a research report on Wednesday. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the company presently has a consensus rating of “Sell”.

Pulmatrix Stock Performance

The business’s 50 day moving average price is $1.36 and its 200-day moving average price is $2.04. The firm has a market cap of $5.99 million, a price-to-earnings ratio of -1.33 and a beta of 1.95.

Pulmatrix (NASDAQ:PULM) last announced its quarterly earnings data on Friday, May 15th. The biotechnology company reported ($0.32) earnings per share for the quarter.

Institutional Investors Weigh In On Pulmatrix

A hedge fund recently bought a new position in Pulmatrix stock. Dimensional Fund Advisors LP acquired a new position in Pulmatrix, Inc. (NASDAQ:PULM) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 10,780 shares of the biotechnology company’s stock, valued at approximately $52,000. Dimensional Fund Advisors LP owned 0.30% of Pulmatrix at the end of the most recent reporting period. Hedge funds and other institutional investors own 11.84% of the company’s stock.

About Pulmatrix

Pulmatrix, Inc is a clinical-stage biopharmaceutical company dedicated to developing inhaled therapies for patients suffering from respiratory diseases. The company’s proprietary iSPERSE® dry-powder formulation platform produces fine microparticles optimized for deep-lung delivery, rapid absorption and consistent dosing, addressing challenges often encountered with traditional inhalation approaches.

Among Pulmatrix’s lead programs is PUR1900, an inhaled therapy designed to treat pulmonary fungal infections such as allergic bronchopulmonary aspergillosis (ABPA).